GRI BIO INC (GRI) Fundamental Analysis & Valuation

NASDAQ:GRI • US3622AW5029

Current stock price

2.1799 USD
-0.05 (-2.25%)
At close:
2.32 USD
+0.14 (+6.43%)
After Hours:

This GRI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. GRI Profitability Analysis

1.1 Basic Checks

  • In the past year GRI has reported negative net income.
  • GRI had a negative operating cash flow in the past year.
  • In the past 5 years GRI always reported negative net income.
  • In the past 5 years GRI always reported negative operating cash flow.
GRI Yearly Net Income VS EBIT VS OCF VS FCFGRI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -137.96%, GRI is doing worse than 82.91% of the companies in the same industry.
  • GRI's Return On Equity of -199.00% is on the low side compared to the rest of the industry. GRI is outperformed by 70.10% of its industry peers.
Industry RankSector Rank
ROA -137.96%
ROE -199%
ROIC N/A
ROA(3y)-261.48%
ROA(5y)-280.2%
ROE(3y)-1860.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRI Yearly ROA, ROE, ROICGRI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K -5K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for GRI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRI Yearly Profit, Operating, Gross MarginsGRI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. GRI Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for GRI has been increased compared to 1 year ago.
  • Compared to 5 years ago, GRI has more shares outstanding
  • GRI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GRI Yearly Shares OutstandingGRI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 100K 200K 300K 400K
GRI Yearly Total Debt VS Total AssetsGRI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

2.2 Solvency

  • Based on the Altman-Z score of -11.38, we must say that GRI is in the distress zone and has some risk of bankruptcy.
  • GRI's Altman-Z score of -11.38 is on the low side compared to the rest of the industry. GRI is outperformed by 75.53% of its industry peers.
  • There is no outstanding debt for GRI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.38
ROIC/WACCN/A
WACCN/A
GRI Yearly LT Debt VS Equity VS FCFGRI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M -10M

2.3 Liquidity

  • A Current Ratio of 3.25 indicates that GRI has no problem at all paying its short term obligations.
  • GRI has a worse Current ratio (3.25) than 60.39% of its industry peers.
  • GRI has a Quick Ratio of 3.25. This indicates that GRI is financially healthy and has no problem in meeting its short term obligations.
  • GRI's Quick ratio of 3.25 is in line compared to the rest of the industry. GRI outperforms 41.94% of its industry peers.
Industry RankSector Rank
Current Ratio 3.25
Quick Ratio 3.25
GRI Yearly Current Assets VS Current LiabilitesGRI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. GRI Growth Analysis

3.1 Past

  • GRI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 95.65%, which is quite impressive.
EPS 1Y (TTM)95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20723.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, GRI will show a very strong growth in Earnings Per Share. The EPS will grow by 25.38% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99%
EPS Next 2Y39.2%
EPS Next 3Y25.38%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRI Yearly Revenue VS EstimatesGRI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 20K 40K 60K 80K
GRI Yearly EPS VS EstimatesGRI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2024 2025 2026 2027 2028 -500K -1M -1.5M

More info and screens

Find the best growth stocksShow best growing peers

1

4. GRI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GRI. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GRI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRI Price Earnings VS Forward Price EarningsGRI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRI Per share dataGRI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200 -300

4.3 Compensation for Growth

  • GRI's earnings are expected to grow with 25.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.2%
EPS Next 3Y25.38%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GRI Dividend Analysis

5.1 Amount

  • GRI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GRI Fundamentals: All Metrics, Ratios and Statistics

GRI BIO INC

NASDAQ:GRI (4/30/2026, 8:00:02 PM)

After market: 2.32 +0.14 (+6.43%)

2.1799

-0.05 (-2.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)01-30
Earnings (Next)05-13
Inst Owners0.15%
Inst Owner Change0%
Ins Owners0%
Ins Owner Change0%
Market Cap3.16M
Revenue(TTM)N/A
Net Income(TTM)-11.96M
Analysts80
Price Target163.2 (7386.58%)
Short Float %9.33%
Short Ratio1.39
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-165.43%
Min EPS beat(2)-294.58%
Max EPS beat(2)-36.27%
EPS beat(4)1
Avg EPS beat(4)-92.4%
Min EPS beat(4)-294.58%
Max EPS beat(4)0.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-75.16%
PT rev (3m)595.65%
EPS NQ rev (1m)90.99%
EPS NQ rev (3m)-27.46%
EPS NY rev (1m)0%
EPS NY rev (3m)-2700%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB 0.53
EV/EBITDA N/A
EPS(TTM)-351.53
EYN/A
EPS(NY)-3.52
Fwd EYN/A
FCF(TTM)-5.94
FCFYN/A
OCF(TTM)-5.94
OCFYN/A
SpS0
BVpS4.14
TBVpS4.14
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -137.96%
ROE -199%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-261.48%
ROA(5y)-280.2%
ROE(3y)-1860.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.25
Quick Ratio 3.25
Altman-Z -11.38
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20723.21%
EPS Next Y99%
EPS Next 2Y39.2%
EPS Next 3Y25.38%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-45.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.79%
EBIT Next 3Y-23.71%
EBIT Next 5Y-20.69%
FCF growth 1Y4.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.22%
OCF growth 3YN/A
OCF growth 5YN/A

GRI BIO INC / GRI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of GRI BIO INC (GRI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to GRI.


What is the valuation status of GRI BIO INC (GRI) stock?

ChartMill assigns a valuation rating of 1 / 10 to GRI BIO INC (GRI). This can be considered as Overvalued.


What is the profitability of GRI stock?

GRI BIO INC (GRI) has a profitability rating of 0 / 10.


Can you provide the financial health for GRI stock?

The financial health rating of GRI BIO INC (GRI) is 6 / 10.


What is the earnings growth outlook for GRI BIO INC?

The Earnings per Share (EPS) of GRI BIO INC (GRI) is expected to grow by 99% in the next year.